

Dengue: Foreshadowing from Ancient Foe

Dr. Richmond Ronald Gomes

Associate Professor, Medicine

Ad-din Women's Medical College Hospital, Dhaka, Bangladesh

***Corresponding author**

Dr. Richmond Ronald Gomes, Ad-din Women's Medical College Hospital, Dhaka, Bangladesh.

Submitted: 15 Aug 2021; **Accepted:** 23 Aug 2021; **Published:** 16 Sept 2021

Citation: Richmond Ronald Gomes. (2021). Dengue: Foreshadowing from Ancient Foe. *Archives of Infect Diseases & Therapy*, 5(3), 60-63.

Abstract

Dengue is a painful, debilitating mosquito-borne disease (female mosquitoes of the *Aedes* genus, principally *Aedes aegypti*) caused by any one of four closely related dengue viruses. It is endemic in tropical and subtropical continent. World health organization (WHO) currently estimates there may be 50 -100 million dengue infections worldwide every year with over 2.5 billion people at risk of dengue. Symptomatic dengue virus infection may manifest as undifferentiated fever, classical dengue fever (with or without unusual hemorrhages), and dengue hemorrhagic fever (with or without shock). Expanded dengue syndrome (EDS) was coined by WHO in the year 2012 to describe cases, which do not fall into either dengue shock syndrome or dengue hemorrhagic fever. The atypical manifestations noted in expanded dengue are multisystem and multifaceted with organ involvement, such as liver, brain, heart, kidney, central/peripheral nervous system, gastrointestinal tract, lympho reticular system.

Keywords: Dengue, Aedes, Dengue Hemorrhagic Fever, Expanded Dengue Syndrome

Introduction

Although in recent years Bangladesh has achieved a remarkable progress in controlling communicable diseases, the country has still been facing a tremendous pressure in respect of public health problems especially controlling the emerging or re-emerging diseases. Dengue ranks as the most important, rapidly emerged disease in recent years and is endemic in all continents. Approximately, half of the world's population is at risk. Up to 50-100 million infections are now estimated to occur annually in over 100 endemic countries including Bangladesh [1]. Bangladesh is situated in the tropical and sub-tropical regions like other Southeast Asian (SE) countries and like them has become a suitable habitat for the dengue vector and its increased transmission.

Discussion

Dengue is the fastest emerging arboviral infection caused by Dengue virus (DENV). It causes a severe flu-like illness, sometimes potentially lethal complications. Dengue virus is a single stranded positive polarity RNA virus, belongs to the family Flaviviridae. It is transmitted through the bite of an infected female mosquito of *Aedes* species - mainly the species *Aedes aegypti* and, to a lesser extent, *Aedes albopictus*. This mosquito also transmits Chikungunya, Zika and Yellow fever viruses [2, 3]. The *Aedes* mosquito breeds in fresh stagnant water. Heavy rainfalls in Bangladesh during the monsoon season and unplanned rapid urbanization with thousands of building sites have created the perfect breeding

ground for the mosquito-borne virus.

There are four dengue virus serotypes, which are designated as DENV-1, DENV-2, DENV-3, and DENV-4. Infection with anyone of these serotypes confers lifelong immunity to that virus serotype. Although all four serotypes are antigenically similar, yet they elicit cross protection for only few months. Secondary infection with dengue serotype 2 or multiple infection with different serotypes enhance chances of occurring more severe form of diseases.

The first recorded case of probable dengue fever was in a Chinese medical encyclopedia from the Jin Dynasty (265-420 AD) which referred to a "water poison" associated with flying insects. The most plausible early reports of dengue epidemics are from 1779 and 1780, when an epidemic swept across Asia, Africa and North America. The first confirmed case report dates from 1789 and is by Benjamin Rush, who coined the term "break bone fever" because of the symptoms of myalgia and arthralgia [4]. Hemorrhagic dengue was first recognized in the 1953 during dengue epidemics in the Philippines and Thailand [5]. and dengue shock syndrome were first noted in Central and South America in 1981 [6]. In Bangladesh, dengue occurred sporadically since 1964 [7]. Literature shows, the first documented case of dengue like fever occurred in 1964, popularly known as "Dacca fever" which later on serologically proved as dengue fever [8]. Dengue caused a serious public health concern, following a sudden outbreak in 2000 where around

5,551 cases and 93 deaths occurred in the country. In 2019 during the early monsoon dengue outbreak with death in Dhaka started in an alarming way and affected number are almost 101354 and total death is 179 according to DGHS although both numbers are higher according to print and electronic media reports. A recent study in 2017 (until February 2018) in Dhaka, described DENV-2 as the dominant type, but also detected some DENV-1 and DENV-3. In the recent years, despite a small sample size, DENV-3 and DEN -4 accounts for most of the cases [9, 10] and these strains are considered deadly as they cause plasma leakage, respiratory distress and organ impairment in patients [11].

The virus passes to humans through the bites of an infective female Aedes mosquito, which mainly acquires the virus while feeding on the blood of an infected person. The full life cycle of dengue fever virus involves the role of mosquitoes as a transmitter (or vector) and humans as the main victim and source of infection. Once humans are infected, humans become the main carriers and multipliers of the virus; serve as a source of the virus for uninfected mosquitoes. The virus circulates in the blood of an infected person for 2 to 7 days, at approximately the same time the person develops a fever. The infected person can transmit the infection via Aedes mosquitoes after the first symptoms appear which normally occur within 4 to 5 days to maximum 12 days.

The pathogenesis of dengue involves a complex interaction between virus and host factors, and remains incompletely understood. The immune system plays a key role in disease pathogenesis. Various mechanisms of severe disease have been suggested, including: (a) Antibody-dependent enhancement or ADE, (b) T-cell mediated immunopathology, (c) Complement activation by virus-antibody complexes and (d) Cytokine abundance. These cytokines along with complement breakdown products (C3a, C5a) activated in DHF/DSS, increases vascular permeability of vascular endothelial cells leading to DSS. Antibody dependent enhancement and inappropriate memory T-cell response are central to the pathogenesis of DHF/DSS. Factors Responsible for DHF/DSS are presence of enhancing and non-neutralizing antibodies, age less than 12 years, female sex, Caucasian race, sequence of infection, infecting serotype (type 3 is most dangerous). Causes of bleeding in dengue syndrome are multifactorial. Proposed causes are abnormal coagulogram, thrombocytopenia, platelet dysfunction, prothrombin complex deficiency secondary to liver involvement, endothelial injury, DIC and prolonged APTT, decreased fibrinogen level, Increased level of fibrinogen degradation product (FDP), Increase level of D-Dimer, consumptive coagulopathy (activation of mononuclear phagocytes), Sequestration of platelet.

Dengue virus infections may be asymptomatic or may lead to undifferentiated fever, dengue fever, or dengue hemorrhagic fever (DHF) with plasma leakage that may lead to hypovolemic shock Dengue Shock Syndrome (DSS). In 2012, the World Health Organization (WHO) has coined the term expanded dengue syndrome (EDS) to describe cases, which do not fall into either dengue shock syndrome or dengue hemorrhagic fever. This has incorporated several atypical findings of dengue affecting various organs of the body.




Figure 1: Clinical Course of Dengue Fever

DHF is characterized by the acute onset of high fever and is associated with signs and symptoms similar to DF in the early febrile phase. Critical phase with plasma leakage is the hallmark of DHF which occurs soon after the end of the febrile phase. Plasma leakage is due to increased capillary permeability. There is a tendency to develop hypovolemic shock (dengue shock syndrome) due to plasma leakage.

DF/DHF patients usually go to critical phase after 3 to 4 days of onset of fever. During this critical phase plasma leakage and high hemoconcentration are documented and patients may develop hypotension. With the leakage of plasma there will increase in hematocrit. A 20% rise of hematocrit from the baseline is indicative of significant plasma leakage. Abnormal hemostasis and leakage of plasma leads to shock, bleeding, DIC, metabolic acidosis and accumulation of fluid in pleural and abdominal cavity. High morbidity and mortality in DHF/DSS are commonly associated with various organ involvements and metabolic derangement. The period of plasma leakage usually persists for 36-48 hrs. Commonly in DHF, platelet count is less than 100000 per/cmm of blood. Significant loss of plasma leads to hypovolemic shock. Even in these shock cases, prior to intravenous fluid therapy, pleural effusion and ascites may not be detected clinically. Radiographic and ultrasound evidence of plasma leakage precedes clinical detection. A right lateral decubitus chest radiograph to detect pleural effusion and gall bladder wall edema is associated with plasma leakage and may precede the clinical detection. Dengue Shock Syndrome is a prevention of Dengue Syndromes when there are criteria of DHF plus signs of circulatory failure, manifested by: rapid and weak pulse, narrow pulse pressure (\leq to 20 mm Hg), hypotension for age, cold clammy skin, restlessness, undetectable pulse and blood pressure.

During the recovery phase the extracellular fluid which was lost due to capillary leakage returns to the circulatory system and signs and symptoms improve. This phase usually after 6-7 days of fever and last for 2-3 days. Longer convalescence may be expected in some of the patients with severe shock, organ involvement and other complications which may require specific treatment. Patient may develop pulmonary oedema due to fluid overload if the fluid replacement is not optimized carefully.

Patients with dengue illness can sometimes develop unusual manifestations such as involvement of liver, kidneys, brain or heart with or without evidence of fluid leakage and therefore do not necessarily fall into the category of DHF named as expanded dengue syndrome or isolated organopathy. These conditions are very rare and management is symptomatic. Such unusual manifestations may be associated with coinfections and comorbidities. However, these manifestations if seen in DHF patients are mostly a result of prolonged shock leading to organ failure.

System	Unusual or atypical manifestation
Neurological	Febrile seizures in young children. Encephalopathy. Encephalitis/aseptic meningitis. Intracranial hemorrhages/thrombosis. Subdural effusions. Mononeuropathies/polyneuropathies/Guillane-Barre Syndrome. Transverse myelitis
Gastrointestin	Hepatitis/fulminant hepatic failure. Acalculous cholecystitis. Acute pancreatitis. Hyperplasia of Peyer's patches. Acute parotitis.
Renal	Acute renal failure. Hemolytic uremic syndrome
Cardiac	Conduction abnormalities. Myocarditis. Pericarditis
Respiratory	Acute respiratory distress syndrome. Pulmonary hemorrhage.
Musculoskelet	Myositis with raised creatine phosphokinase (CPK). Rhabdomyolysis
Lymphoreticul	Infection associated haemophagocytic syndrome. IAHS or Haemophagocytic lymphohistiocytosis (HLH), idiopathic thrombocytopenic purura(ITP). Spontaneous splenic rupture. Lymph node infarction
Eye	Macular hemorrhage. Impaired visual acuity. Optic neuritis.
Others	Post-infectious fatigue syndrome, depression, hallucinations, psychosis, alopecia

Expanded Dengue Syndrome

In 2021, dengue infection has emerged with changing spectrum of presentations in Bangladesh. Atypical presentations are observed more frequently. There is persistence of fever beyond seven days, absence of fever, only back pain, enteritis as presenting feature, rapid development of pancreatitis, cholecystitis, fulminant hepatic failure, acute renal failure or unusual hemorrhage during febrile phase, development of thrombocytopenia in mid febrile phase and persistence of thrombocytopenia beyond critical phase, high elevation of CRP and D dimer.

The management of DS is based on clinical judgment rather than laboratory evaluations alone. However, few indirect tests may be suggestive of DS from the outset. Complete blood count including total leucocyte count, total platelet count and hematocrit should be done on first consultation (within first week) of the patient to have the baseline. The change in total white cell count (≤ 5000 cells/mm³) and ratio of neutrophils to lymphocyte (neutrophils < lymphocytes) is useful to predict the critical period of plasma leakage. This finding precedes thrombocytopenia or rising hematocrit. These changes seen in DF and DHF. Mild thrombocytopenia (100,000 to 150,000 cells/mm³) is common and about half of all DF patients have platelet count below 100,000 cells/mm³; A sudden drop in platelet count to below 100,000 occurs before the onset of shock or subsidence of fever. The level of platelet count is correlated with severity of DHF. Severe thrombocytopenia (<100,000/mm³) usually precedes/accompanies overt plasma leakage. A sudden rise in hematocrit is observed simultaneously or shortly after the drop in platelet count. Hemoconcentration or rising hematocrit by 20% from the baseline, e.g. from hematocrit of 35% to $\geq 42\%$ is objective evidence of leakage of plasma. AST and ALT levels are frequently elevated in both adults and children with DF and DHF.

Regarding dengue diagnostic tests, detection of antigen: NS1 antigen is used in early phase. The ELISA NS1 (non-structural protein 1) antigen is positive on first day of illness. This test becomes negative from day 4-5 of illness. Anti-dengue IgM specific antibodies can be detected after 5 days of the onset of fever and highest level achieved after 7 days. In primary dengue infection- IgM will be more than IgG early period and sed IgG at 9 or 10th day of fever. In secondary dengue infection- higher elevation of anti-dengue specific IgG antibodies and lower levels of IgM.

Dengue patients without warning signs (persistent vomiting, severe abdominal pain, lethargy, restlessness, bleeding, giddiness, pale, cold clammy skin, less or no urine output for 4-6 hours) can be managed at home with adequate oral fluid intake. Patient with warning signs should be admitted for in-hospital management for close observation as they approach the critical phase. Rapid fluid replacement in patients with warning signs is the key to prevent progression to the shock state. Those with co-existing conditions or risk factors (pregnancy, elderly, diabetes, hypertension, renal failure, obesity, chronic hemolytic disease) may need careful monitoring and hospitalization even without warning signs. Patients with severe dengue require emergency treatment and urgent referral because they are in the critical phase of the disease and have severe plasma leakage leading to dengue shock and/or fluid accumulation with distress, severe organ impairment (hepatic damage, renal impairment).myocarditis, cardiomyopathy, encephalopathy or encephalitis, severe metabolic abnormalities (metabolic acidosis, severe hypocalcaemia etc).These patient should be managed with appropriate intravenous fluids(crystalloid or if needed colloid), Whole blood or blood products(fresh frozen plasma or platelet apheresis) and other supportive treatment(sodium bi carbonate, calcium gluconate, intravenous dextrose, treatment of renal failure and hyperkalemia). The patients should be advised to avoid acetylsalicylic acid (aspirin), mefenemic acid, ibuprofen or other NSAIDs, steroids and antibiotics.

Signs of recovery from dengue are stable pulse, blood pressure and breathing rate, normal temperature, no evidence of external or internal bleeding, return of appetite no vomiting, no abdominal pain good urinary output stable hematocrit at baseline level convalescent confluent petechiae rash or itching, especially on the extremities. The admitted patient can be discharged from hospital if there is no fever for at least 24 hours without the usage of anti-pyretic drugs, at least two days have lapsed artier recovery from shock, good general condition with improving appetite, normal hematocrit at baseline value or around 38 - 40 % when baseline value is not known.no distress from pleural effusions.no ascites, platelet count has risen above 50,000 /mm³, no other complications

Dengue, an emerging disease, will remain in Bangladesh and will continue to constitute a serious public health problem as is happening worldwide. The changing epidemiology should be clearly understood, and constant monitoring is needed, including extending the surveillance areas and addressing the challenges to reduce the impact of the disease on public health and the economy of the country. It may be very challenging to root up the disease from the supply side, and a long-term investment is needed to achieve behavioral changes in the urban population to join the fight against the Aedes mosquitoes.

From a public health standpoint, mass mobility events (e.g., Eid exodus, Hajj pilgrimage) can sometimes be reasons for major concern if their location and timing coincide with major outbreak [12]. Such unexpected coincidence could facilitate outbreaks (especially with highly contagious viruses) morphing into an epidemic or even pandemic (depending on other factors like ease of transmission and favorability of climate factors). The ongoing outbreak of coronavirus in Wuhan, China, can be a recent example of this. Transmission and spread of infectious diseases, including dengue and other Aedes mosquito-borne diseases (chikungunya and Zika), especially during an outbreak can therefore present an immense challenge for public health safety, as there is no vaccine against dengue.

Conclusion

Prevention and control of dengue in Bangladesh, is not a sole responsibility for any single ministry and or its agencies. It needs effective and timely coordination, collaboration and partnership, among all the concerned ministries and their agencies, led by the Ministry of Health and Family Welfare. Furthermore, strengthening of the existing efforts including capacity building and resource mobilization, and integrated surveillance, sustainable vector control, optimum and active community participation, and adequate monitoring and periodic evaluation throughout the year across the country, considering it an endemic disease, are strongly recommended. Attempts at conducting risk assessment based on early warning signs therefore need to incorporate social factors and mass movement events along with the climate factors

References

1. World Health Organization. (2012-2020). Global strategy for dengue prevention and control.
2. Levinson, W. (2014). Review of medical microbiology and immunology. McGraw-Hill Education.
3. Davidson's Principles and Practice of Medicine. Editors: Ralston SH, Penman ID, Strachan MWJ, Hobson RP. 23rd Edition. 2019. Elsevier, Edinburgh.
4. Dengue Virus Net. (accessed at <http://www.denguevirusnet.com>).
5. World Health Organization. (2014). Dengue and severe dengue (No. WHO-EM/MAC/032/E). World Health Organization. Regional Office for the Eastern Mediterranean.
6. Gould, E. A., & Solomon, T. (2008). Pathogenic flaviviruses. *The Lancet*, 371(9611), 500-509.
7. Sharmin, S., Viennet, E., Glass, K., & Harley, D. (2015). The emergence of dengue in Bangladesh: epidemiology, challenges and future disease risk. *Transactions of The Royal Society of Tropical Medicine and Hygiene*, 109(10), 619-627.
8. Mobarak, M. R., Islam, M. R., Bhuiyan, A. T., Akand, N., & Begum, F. (2017). Evaluation of Dengue Fever in a tertiary care children hospital of Bangladesh. *Northern International Medical College Journal*, 9(1), 274-277.
9. Ahmad, F. U., Paul, S. K., Aung, M. S., Mazid, R., Alam, M., Ahmed, S., ... & Kobayashi, N. (2020). Co-circulation of dengue virus type 3-genotype I and type 2-Cosmopolitan genotype in 2018 outbreak in Dhaka, Bangladesh. *New microbes and new infections*, 33, 100629.
10. Shirin, T., Muraduzzaman, A. K. M., Alam, A. N., Sultana, S., Siddiqua, M., Khan, M. H., ... & Flora, M. S. (2019). Largest dengue outbreak of the decade with high fatality may be due to reemergence of DEN-3 serotype in Dhaka, Bangladesh, necessitating immediate public health attention. *New microbes and new infections*, 29.
11. Faisal Mahmud. (2019). Why is Bangladesh Grappling with a record dengue fever outbreak? 7 Aug 2019. Available from: www.aljazeera.com/news/2019/8/7/why-is-bangladesh-grappling-with-a-record-dengue-fever-outbreak
12. Altassan, K. K., Morin, C., Shocket, M. S., Ebi, K., & Hess, J. (2019). Dengue fever in Saudi Arabia: A review of environmental and population factors impacting emergence and spread. *Travel medicine and infectious disease*, 30, 46-53.

Copyright: ©2021 Dr. Richmond Ronald Gomes., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.